Crestwood Advisors Group LLC Has $3.61 Million Stock Position in Boston Scientific Co. (NYSE:BSX)

Crestwood Advisors Group LLC decreased its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 1.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 62,365 shares of the medical equipment provider’s stock after selling 717 shares during the quarter. Crestwood Advisors Group LLC’s holdings in Boston Scientific were worth $3,605,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of BSX. International Assets Investment Management LLC acquired a new position in shares of Boston Scientific during the 1st quarter worth $54,000. Acadian Asset Management LLC acquired a new position in Boston Scientific in the 1st quarter valued at $35,000. Prudential PLC acquired a new position in Boston Scientific in the 1st quarter valued at $1,076,000. Cetera Investment Advisers grew its stake in Boston Scientific by 24.0% in the 1st quarter. Cetera Investment Advisers now owns 28,793 shares of the medical equipment provider’s stock valued at $1,275,000 after buying an additional 5,581 shares during the last quarter. Finally, Sequoia Financial Advisors LLC acquired a new position in Boston Scientific in the 1st quarter valued at $230,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. TD Cowen raised their target price on shares of Boston Scientific from $65.00 to $77.00 and gave the company an “outperform” rating in a research note on Thursday, March 7th. Evercore ISI increased their price target on shares of Boston Scientific from $68.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Needham & Company LLC increased their price target on shares of Boston Scientific from $60.00 to $71.00 and gave the company a “buy” rating in a report on Thursday, February 1st. Royal Bank of Canada increased their price target on shares of Boston Scientific from $67.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Finally, Raymond James increased their price target on shares of Boston Scientific from $67.00 to $73.00 and gave the company a “strong-buy” rating in a report on Thursday, February 1st. Two equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and a consensus target price of $68.14.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 16,351 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $69.30, for a total transaction of $1,133,124.30. Following the transaction, the executive vice president now directly owns 50,638 shares in the company, valued at approximately $3,509,213.40. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $66.35, for a total value of $463,322.05. Following the sale, the executive vice president now directly owns 53,788 shares in the company, valued at approximately $3,568,833.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP John Bradley Sorenson sold 16,351 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $69.30, for a total transaction of $1,133,124.30. Following the sale, the executive vice president now owns 50,638 shares in the company, valued at $3,509,213.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,979 shares of company stock worth $3,418,529. Company insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

BSX stock traded down $0.77 during trading on Friday, hitting $68.07. 4,995,155 shares of the stock traded hands, compared to its average volume of 4,947,475. Boston Scientific Co. has a one year low of $48.35 and a one year high of $69.21. The stock has a market cap of $99.87 billion, a price-to-earnings ratio of 63.62, a P/E/G ratio of 2.41 and a beta of 0.78. The company has a 50 day simple moving average of $66.99 and a 200 day simple moving average of $59.32. The company has a current ratio of 1.32, a quick ratio of 0.82 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, beating the consensus estimate of $0.51 by $0.04. Boston Scientific had a return on equity of 15.99% and a net margin of 11.19%. The company had revenue of $3.73 billion during the quarter, compared to analysts’ expectations of $3.59 billion. During the same period last year, the firm earned $0.45 EPS. Equities analysts expect that Boston Scientific Co. will post 2.25 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.